| Literature DB >> 26894538 |
Chia Ying Huang1, Vincent Olieric2, Pikyee Ma1, Nicole Howe1, Lutz Vogeley1, Xiangyu Liu3, Rangana Warshamanage2, Tobias Weinert2, Ezequiel Panepucci2, Brian Kobilka3, Kay Diederichs4, Meitian Wang2, Martin Caffrey1.
Abstract
Here, a method for presenting crystals of soluble and membrane proteins growing in the lipid cubic or sponge phase for in situ diffraction data collection at cryogenic temperatures is introduced. The method dispenses with the need for the technically demanding and inefficient crystal-harvesting step that is an integral part of the lipid cubic phase or in meso method of growing crystals. Crystals are dispersed in a bolus of mesophase sandwiched between thin plastic windows. The bolus contains tens to hundreds of crystals, visible with an in-line microscope at macromolecular crystallography synchrotron beamlines and suitably disposed for conventional or serial crystallographic data collection. Wells containing the crystal-laden boluses are removed individually from hermetically sealed glass plates in which crystallization occurs, affixed to pins on goniometer bases and excess precipitant is removed from around the mesophase. The wells are snap-cooled in liquid nitrogen, stored and shipped in Dewars, and manually or robotically mounted on a goniometer in a cryostream for diffraction data collection at 100 K, as is performed routinely with standard, loop-harvested crystals. The method is a variant on the recently introduced in meso in situ serial crystallography (IMISX) method that enables crystallographic measurements at cryogenic temperatures where crystal lifetimes are enormously enhanced whilst reducing protein consumption dramatically. The new approach has been used to generate high-resolution crystal structures of a G-protein-coupled receptor, α-helical and β-barrel transporters and an enzyme as model integral membrane proteins. Insulin and lysozyme were used as test soluble proteins. The quality of the data that can be generated by this method was attested to by performing sulfur and bromine SAD phasing with two of the test proteins.Entities:
Keywords: AlgE; DgkA; GPCR; PepTSt; bromine SAD; cubic phase; experimental phasing; in meso; in situ; insulin; kinase; lipid cubic phase; membrane protein; mesophase; serial crystallography; sponge phase; sulfur SAD; transporter; β2-adrenergic receptor
Mesh:
Substances:
Year: 2016 PMID: 26894538 PMCID: PMC4756617 DOI: 10.1107/S2059798315021683
Source DB: PubMed Journal: Acta Crystallogr D Struct Biol ISSN: 2059-7983 Impact factor: 7.652
Figure 1Experimental setup for IMISXcryo data collection at 100 K and the steps involved in sample preparation. (a) A view of an IMISX well on a goniometer with the crystal-laden mesophase bolus positioned in the X-ray beam and in the cryostream at 100 K for SX data collection on beamline PXI (X06SA) at the SLS. The yellow arrow indicates the direction of the X-ray beam. (b) Goniometer base with composite support on the pin (left) ready for attachment of the IMISX well (bottom right). The insert (dashed square) is a view from above of the goniometer base (left) to show the slight curvature in the attached composite support. (c) IMISX well mounted on a goniometer base and seated on a moist paper towel. M, mesophase bolus with crystals; P, precipitant solution; S, composite support. (d) As in (c) where the well has been trimmed to fit into a cryo-vial and to provide access to the precipitant solution. (e) A cotton bud is used to wick away most of the precipitant solution from around the mesophase bolus. A small amount of precipitant is left in place to prevent callapse of the well. The mounted sample is snap-cooled in liquid nitrogen and placed in a cryo-vial for transfer to a Dewar. (f) A view of the well (W) and support (S) in (e) from above to show the slight curvature in the well that confers structural stability to the sample in the cryostream.
Figure 2Images of crystals in IMISXcryo wells in a cryostream at 100 K as viewed by a high-resolution in-line microscope. (a) Insulin. (b) Lysozyme. (c) AlgE. (d) PepTSt. (e) β2AR. (f) DgkA. Arrows point to crystals in the mesophase. DgkA crystals were grown at 277 K. All others were grown at 293 K.
Facts and figures used to estimate the accumulated dose per crystal for the IMISXcryo and IMISX RT studies
| Experiment | IMISXcryo | IMISX RT | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Protein | Insulin-N | Lyso-N | AlgE | PepTSt | β2AR | DgkA | Insulin-S | Lyso-Br | Insulin-N |
| Crystal size (µm) | 30 × 30 × 30 | 15 × 15 × 30 | 15 × 15 × 150 | 20 × 20 × 30 | 5 × 10 × 30 | 20 × 20 × 50 | 30 × 30 × 30 | 15 × 15 × 30 | 30 × 30 × 30 |
| Wavelength (Å) | 0.97857 | 1 | 0.97856 | 0.97852 | 1.0332 | 1 | 2.06643 | 0.91881 | 1 |
| Flux (photons s−1) | 5.9 × 1010 | 8.0 × 1010 | 5.0 × 1011 | 7.4 × 1010 | 3.2 × 1011 | 1.8 × 1011 | 4.3 × 1010 | 3.4 × 1010 | 2.0 × 1011 |
| Beam size (µm) | 10 × 18 | 10 × 30 | 15 × 20 | 10 × 18 | 10 × 18 | 10 × 18 | 15 × 20 | 10 × 30 | 10 × 30 |
| Estimated dose rate | 0.157 | 0.133 | 0.798 | 0.197 | 0.937 | 0.492 | 0.306 | 0.096 | 0.333 |
| Oscillation per exposure (deg s−1) | 0.4/0.2 | 0.1/0.1 | 0.1/0.1 | 0.1/0.3 | 0.1/0.3 | 0.1/0.1 | 0.1/0.1 | 0.1/0.1 | 0.2/0.05 |
| Oscillation range per crystal (°) | 60 | 40 | 20, 25, 25, 30 | 60 | 3 | 20–40 | 60 | 30 | 5 |
| Exposure time per crystal (s) | 30 | 40 | 20, 25, 25, 30 | 180 | 9 | 20–40 | 60 | 30 | 1.25 |
| Estimated accumulated dose per crystal | 4.7 | 5.3 | 16.0–23.9 | 35.4 | 8.4 | 9.8–19.7 | 18.4 | 2.9 | 0.42 |
| Total No. of crystals | 1 | 2 | 1 | 2 | 104 | 12 | 6 | 8 | 25 |
| Total angular range per data set (°) | 60 | 80 | 100 | 120 | 312 | 280 | 360 | 240 | 125 |
| Total exposure time per data set (s) | 30 | 80 | 100 | 360 | 936 | 280 | 360 | 240 | 31.25 |
| Total dose per data set (MGy) | 4.7 | 10.6 | 79.8 | 70.8 | 877 | 137.8 | 110.2 | 23 | 10.4 |
Estimate based on equation (5) in Holton (2009 ▸). For lyso-Br crystals at the Br K edge, the ‘dose-doubling’ effect of bromide has been accounted for.
Data-collection and refinement statistics for IMISX samples
All data-processing statistics are reported with Friedel pairs merged except for insulin-S and lyso-Br. Values in parentheses are for the highest resolution shell.
| Insulin-N | Insulin-N | Lyso-N | AlgE | PepTSt | β2AR | DgkA | Insulin-S | Lyso-Br | |
|---|---|---|---|---|---|---|---|---|---|
| PDB code |
|
|
|
|
|
|
|
|
|
| Crystal-growth temperature (K) | 293 | 293 | 293 | 293 | 293 | 293 | 277 | 293 | 293 |
| Data collection | |||||||||
| Temperature (K) | 293 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| Phasing method | MR | MR | MR | MR | MR | MR | MR | S-SAD | Br-SAD |
| Space group |
|
|
|
|
|
|
|
|
|
| Unit-cell parameters | |||||||||
|
| 79.71, 79.71, 79.71 | 78.36, 78.36, 78.36 | 77.70, 77.70, 38.94 | 46.33, 66.35, 176.84 | 100.16, 109.52, 111.47 | 108.04, 170.58, 40.44 | 75.61, 93.19, 142.74 | 78.20, 78.20, 78.20 | 78.28, 78.28, 38.12 |
| α, β, γ (°) | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 | 90, 106.30, 90 | 90, 90, 90 | 90, 90, 90 | 90, 90, 90 |
| Unit-cell volume (Å3) | 506452 | 481153 | 235092 | 543605 | 1222773 | 745287 | 1005760 | 478212 | 233590 |
| Wavelength (Å) | 1.0 | 0.97857 | 1 | 0.97856 | 0.97852 | 1.0332 | 1 | 2.06643 | 0.91881 |
| ISa threshold | 5 | — | — | — | — | 5 | 3 | 3 | — |
| CCset cutoff | — | — | — | — | — | — | 0.9 | 0.9 | — |
| No. of crystals | 25 | 1 | 2 | 1 | 2 | 104 | 12 | 6 | 8 |
| Resolution (Å) | 50–1.80 (1.85–1.80) | 50–1.50 (1.54–1.50) | 50–1.70 (1.74–1.70) | 50–2.40 (2.46–2.40) | 50–2.40 (2.46–2.40) | 50–2.50 (2.57–2.50) | 50–2.80 (2.87–2.80) | 50–2.40 (2.46–2.40) | 50–1.50 (1.54–1.50) |
|
| 0.295 (2.354) | 0.123 (1.420) | 0.195 (1.650) | 0.162 (1.186) | 0.122 (0.999) | 0.203 (2.084) | 0.244 (2.982) | 0.118 (0.712) | 0.250 (2.233) |
|
| 0.081 (0.652) | 0.049 (0.579) | 0.082 (0.692) | 0.086 (0.612) | 0.059 (0.487) | 0.085 (0.879) | 0.080 (1.012) | 0.030 (0.309) | 0.746 (0.688) |
| 〈 | 6.96 (0.88) | 9.08 (1.21) | 6.16 (1.10) | 5.98 (1.45) | 9.31 (2.18) | 7.27 (1.11) | 4.42 (1.00) | 19.50 (2.00) | 6.39 (0.97) |
| Completeness (%) | 100 (100) | 99.9 (100) | 99.7 (100) | 92.6 (90.8) | 99.4 (98.8) | 95.1 (91.0) | 98.8 (98.6) | 99.9 (99.5) | 99.4 (92.0) |
| Multiplicity | 13.2 (13.0) | 6.4 (6.0) | 5.5 (5.7) | 3.6 (3.8) | 4.3 (4.2) | 5.7 (5.6) | 9.3 (8.7) | 16.0 (5.3) | 11.2 (10.5) |
| CC1/2 | 0.99 (0.46) | 0.99 (0.46) | 0.99 (0.32) | 0.99 (0.62) | 0.99 (0.62) | 0.99 (0.21) | 0.99 (0.36) | 0.998 (0.86) | 0.98 (0.38) |
| CCanom
| — | — | — | — | — | — | — | 0.47 | 0.44 |
| Mosaicity | 0.11 | 0.14 | 0.09 | 0.12 | 0.17 | 0.12 | 0.25 | 0.16 | 0.12 |
| Refinement | |||||||||
| Resolution (Å) | 39.85–1.80 | 38.76–1.50 | 39.55–1.70 | 25.22–2.40 | 45.68–2.40 | 43.96–2.50 | 46.52–2.80 | 27.70–2.41 | 35.06–1.50 |
| No. of reflections | 7975 | 13002 | 13594 | 20520 | 24159 | 23086 | 25188 | 6025 | 35932 |
|
| 0.17/0.21 | 0.16/0.17 | 0.18/0.22 | 0.22/0.26 | 0.21/0.25 | 0.21/0.26 | 0.24/0.28 | 0.17/0.22 | 0.18/0.21 |
| No. of atoms | |||||||||
| Protein | 414 | 814 | 1019 | 3222 | 3475 | 3546 | 4444 | 414 | 1019 |
| Ligand/ion | 10 | 37 | 21 | 233 | 502 | 210 | 260 | 21 | 19 |
| Water | 30 | 63 | 96 | 23 | 64 | 53 | 13 | 31 | 141 |
|
| |||||||||
| Protein | 24.59 | 21.10 | 22.36 | 49.16 | 55.52 | 64.45 | 93.72 | 33.04 | 20.11 |
| Ligand/ion | 41.86 | 47.34 | 35.28 | 68.58 | 71.79 | 86.14 | 113.75 | 53.68 | 30.53 |
| Water | 36.05 | 31.63 | 27.14 | 46.03 | 53.43 | 61.90 | 89.98 | 41.49 | 27.79 |
| R.m.s. deviations | |||||||||
| Bond lengths (Å) | 0.012 | 0.009 | 0.008 | 0.010 | 0.005 | 0.006 | 0.004 | 0.002 | 0.007 |
| Bond angles (°) | 1.094 | 1.045 | 1.022 | 1.220 | 0.932 | 1.487 | 0.580 | 0.514 | 1.038 |
| Ramachandran plot | |||||||||
| Favoured (%) | 98.0 | 98.0 | 99.24 | 95.70 | 98.19 | 98.62 | 99.65 | 98.00 | 98.47 |
| Allowed (%) | 2.0 | 2.00 | 0.76 | 4.00 | 1.81 | 1.38 | 0.35 | 2.00 | 1.53 |
| Outliers (%) | 0 | 0 | 0 | 0.30 | 0 | 0 | 0 | 0 | 0 |
|
| 3.6 | 3.5 | 5.4 | 6.6 | 9.1 | 5.5 | 6.8 | 2.4 | 2.5 |
R p.i.m. was calculated as R meas/(multiplicity)1/2.
Anomalous correlation coefficient evaluated with data truncated to 2.4 Å resolution for insulin-S and to 2.0 Å resolution for lyso-Br.
For IMISX data, mosaicity is reported as the median over all crystals.
Data-collection and refinement statistics for reference loop-harvested crystals at 100 K
All data-processing statistics are reported with Friedel pairs merged. Values in parentheses are for the highest resolution shell.
| Insulin-N | PepTSt | β2AR | DgkA | |
|---|---|---|---|---|
| PDB code |
|
|
|
|
| Crystal-growth temperature (K) | 293 | 293 | 293 | 277 |
| Data collection | ||||
| Phasing method | MR | MR | MR | MR |
| Space group |
|
|
|
|
| Unit-cell parameters | ||||
|
| 77.51, 77.51, 77.51 | 101.57, 110.25, 110.34 | 106.73, 170.42, 40.30 | 75.32, 91.34, 143.36 |
| α, β, γ (°) | 90, 90, 90 | 90, 90, 90 | 90, 105.94, 90 | 90, 90, 90 |
| Unit-cell volume (Å3) | 465665 | 1235598 | 733014 | 986278 |
| Wavelength (Å) | 1.03321 | 1.03321 | 1.03321 | 1 |
| No. of crystals | 1 | 1 | 2 | 1 |
| Resolution (Å) | 50–1.50 (1.54–1.50) | 50–2.40 (2.46–2.40) | 50–3.80 (3.90–3.80) | 50–2.80 (2.87–2.80) |
|
| 0.057 (1.127) | 0.097 (0.745) | 0.526 (1.676) | 0.189 (0.953) |
|
| 0.022 (0.453) | 0.047 (0.357) | 0.205 (0.783) | 0.076 (0.402) |
| 〈 | 15.45 (1.49) | 12.00 (2.26) | 3.76 (0.96) | 7.71 (1.61) |
| Completeness (%) | 99.9 (100) | 99.8 (99.9) | 99.6 (98.8) | 99.6 (98.9) |
| Multiplicity | 6.5 (6.2) | 4.4 (4.36) | 6.5 (4.6) | 6.2 (5.6) |
| CC1/2 | 0.99 (0.55) | 0.99 (0.68) | 0.97 (0.23) | 0.99 (0.64) |
| Mosaicity (°) | 0.07 | 0.07 | 0.20 | 0.08 |
| Refinement | ||||
| Resolution (Å) | 38.76–1.50 | 46.13–2.40 | 49.62–3.80 | 45.67–2.80 |
| No. of reflections | 12580 | 24537 | 6835 | 24904 |
|
| 0.18/0.19 | 0.21/0.23 | 0.24/0.27 | 0.22/0.27 |
| No. of atoms | ||||
| Protein | 814 | 3475 | 3546 | 4490 |
| Ligand/ion | 37 | 503 | 186 | 352 |
| Water | 39 | 75 | 0 | 42 |
|
| ||||
| Protein | 34.84 | 51.78 | 79.42 | 57.01 |
| Ligand/ion | 59.25 | 67.15 | 94.72 | 79.69 |
| Water | 44.43 | 47.69 | 0 | 51.50 |
| R.m.s. deviations | ||||
| Bond lengths (Å) | 0.006 | 0.006 | 0.006 | 0.004 |
| Bond angles (°) | 0.920 | 1.028 | 1.144 | 0.802 |
| Ramachandran plot | ||||
| Favoured (%) | 98.00 | 98.64 | 97.94 | 98.62 |
| Allowed (%) | 2.00 | 1.36 | 2.06 | 1.38 |
| Outliers (%) | 0 | 0 | 0 | 0 |
|
| 2.4 | 7.4 | 5.6 | 6.7 |
R p.i.m. was calculated as R meas/(multiplicity)1/2.
Sample consumption and diffraction measurement statistics
| Temperature (K) | 100 | 293 | 100 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Presentation | Loop |
|
| ||||||||||
| Protein | Insulin-N | PepTSt | β2AR | DgkA | Insulin-N | Insulin-N | Lyso-N | AlgE | PepTSt | β2AR | DgkA | Insulin-S | Lyso-Br |
| Lipid | 9.9 | 7.8 | 9.9 + C | 7.8 | 9.9 | 9.9 | 9.9 | 7.8 | 7.8 | 9.9 + C | 7.8 | 9.9 | 9.9 |
| Mesophase per well (nl) | 200 | 50 | 30 | 50 | 200 | 200 | 200 | 50 | 50 | 30 | 50 | 200 | 200 |
| Lipid/protein solution (by volume) | 3/2 | 1/1 | 3/2 | 1/1 | 3/2 | 3/2 | 3/2 | 1/1 | 1/1 | 3/2 | 1/1 | 3/2 | 3/2 |
| Protein concentration (mg ml−1) | 35 | 10 | 48 | 12 | 35 | 35 | 50 | 10 | 10 | 48 | 12 | 35 | 50 |
| No. of wells | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 5 | 1 | 1 |
| No. of crystals | 1 | 1 | 2 | 1 | 214 | 1 | 2 | 1 | 2 | 149 | 44 | 14 | 8 |
| No. of useful crystals | 1 | 1 | 2 | 1 | 25 | 1 | 2 | 1 | 2 | 104 | 12 | 6 | 8 |
| Lipid (nl) | 120 | 25 | 18 | 25 | 240 | 120 | 120 | 25 | 25 | 18 | 125 | 120 | 120 |
| Protein (µg) | 2.8 | 0.25 | 0.576 | 0.3 | 5.6 | 2.8 | 4 | 0.25 | 0.25 | 0.576 | 1.5 | 2.8 | 4 |
| Total angular range per crystal (°) | 60 | 120 | 120, 240 | 180 | 5 | 60 | 50 | 40 | 60, 90 | 3 | 20, 30, 40 | 60 | 40 |
| Useful angular range per crystal (°) | 60 | 120 | 120, 240 | 180 | 5 | 60 | 40 | 20, 25, 30 | 60 | 3 | 20, 30, 40 | 60 | 30 |
| Indexing rate | 100 | 100 | 100 | 100 | 11.7 | 100 | 80 | 62.5 | 80 | 69.8 | 25.3 | 42.9 | 75 |
| Oscillation per frame (°) | 0.1 | 0.1 | 0.2 | 0.2 | 0.2 | 0.4 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| Exposure time per frame (s) | 0.1 | 0.1 | 0.1 | 0.1 | 0.05 | 0.2 | 0.1 | 0.1 | 0.3 | 0.3 | 0.1 | 0.1 | 0.1 |
| Total angular range (°) | 60 | 120 | 360 | 180 | 125 | 60 | 80 | 100 | 120 | 312 | 280 | 360 | 240 |
The lipid shown refers to the hosting MAG. C indicates that cholesterol was included as an additive lipid.
The total angular range measured varied from crystal to crystal.
The angular range used in processing varied from crystal to crystal.
The indexing rate was calculated as follows: 100 × [(No. of useful crystals) × (useful angular range per crystal)]/[(No. of crystals) × (total angular range per crystal)].
Figure 3Structures of four integral membrane proteins solved using the IMISXcryo method. (a) AlgE. (b) PepTSt. (c) β2AR. (d) DgkA. 2F o − F c electron-density maps for ligands, lipids, ions and other nonproteinaceous molecules in the structures are shown as a blue mesh contoured at 1σ. Structures are shown in cartoon and surface representation and are coloured light green. Ions are shown as spheres: calcium, green; sodium, purple; zinc, grey. The resolutions of the corresponding structures are 2.4 Å (AlgE, PepTSt), 2.5 Å (β2AR) and 2.8 Å (DgkA). Stick models show C (yellow), N (blue) and O (red) atoms.
Figure 4Electron-density maps of ligands bound to PepTSt and β2AR in crystal structures solved by the IMISXcryo method at resolutions of 2.4 and 2.5 Å, respectively. (a, b) Views into the peptide-binding pocket of PepTSt reveal the dipeptide Ala-Phe in well defined density. (c, d) Views into the ligand-binding pocket of β2AR reveal the partial inverse agonist carazolol in well defined density. Ligands are shown with yellow C atoms and with an F o − F c map (green mesh) contoured at 3σ. 2F o − F c maps are contoured at 1σ (blue mesh). Relevant residues are highlighted as sticks with grey C atoms. The protein backbone is shown in thin ribbon representation coloured green. Helices (H) and an extracellular loop (ECL) are indicated following the notation in the original literature. Stick models include N (blue) and O (red) atoms.
Figure 5Distribution of reflection multiplicity and crystal orientation in an IMISXcryo data set recorded using 104 β2AR crystals. (a) Blue, observed multiplicity. Red, binomial distribution of multiplicity predicted for an effective crystal rotation range of 2.5°. (b) Projection of the unit-cell a axis along the X-ray beam direction (red dot). The horizontal axis (dotted line) is the rotation-spindle direction and the vertical axis (solid line) is perpendicular to both the X-ray beam and rotation-spindle directions. Each blue diamond represents one crystal. For any given crystal in the set, the angle between its unit-cell axis and the X-ray beam direction is indicated by the position of the corresponding diamond on a circle. These range from 90° on the limiting circle to 0 or 180° at the centre of the circle. (c) Projection of the unit-cell b axis along the X-ray beam direction. (d) Projection of the unit-cell c axis along the X-ray beam direction. The skewed distribution in (a) is consistent with the preferential crystal orientation with the a axis of the unit cell close to the X-ray beam direction (b).